Last reviewed · How we verify

Hypokalemia — Treatment Landscape & Competitive Intelligence

Hypokalemia (disease) competitive landscape: 5 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

5 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Hypokalemia, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Plegisol In Plastic Container CALCIUM CHLORIDE Pfizer calcium chloride 1971-01-01
Sodium Lactate In Plastic Container SODIUM LACTATE Pfizer sodium lactate 1971-01-01
Potassium Acetate Potassium Acetate Pfizer potassium acetate 1971-01-01
Micro-K 10 POTASSIUM CHLORIDE Nesher Pharms potassium chloride Carbonic anhydrase 4 1965-01-01
Aspart Aspart Emory University Insulin Analog [EPC] Aminoacylase-1, Argininosuccinate synthase, Aspartate aminotransferase, cytoplasmic

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. · 3 drugs in Hypokalemia
  2. Pfizer · 3 drugs in Hypokalemia
  3. Emory University · 1 drug in Hypokalemia
  4. Nesher Pharms · 1 drug in Hypokalemia

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Hypokalemia:

Cite this brief

Drug Landscape (2026). Hypokalemia — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/hypokalemia. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing